Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: An old(er) problem

Journal of Clinical Oncology

Volumn 22, Issue 23, 2004, Pages 4608-4610

  Schott, Anne ^a   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; TAMOXIFEN;

AGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COMORBIDITY; DRUG TOLERABILITY; EDITORIAL; ELDERLY CARE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 16544374474     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.961     Document Type: Editorial

References (31)

1. Peto R, Boreham J, Clarke M, et al: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355:1822, 2000
2. Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
3. Early Breast Cancer Trialist's Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
4. Muss HB: Factors used to select adjuvant therapy of breast cancer in the United States: An overview of age, race, and socioeconomic status. J Natl Cancer Inst Monogr No. 30:52-55, 2001
5. Fargeot P, Bonneterre J, Roché H, et al: Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of French Adjuvant Study Group 08 Trial. J Clin Oncol 22:4622-4630, 2004
6. Fisher B, Slack N, Katrych D, et al: Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528-534, 1975
7. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
8. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
9. Goldhirsch A, Gelman RS, Gelber RD, et al: Treatment of breast cancer in elderly patients. Lancet 336:564, 1990
10. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
11. Gelman RS, Taylor SG 4th: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984
12. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 18:1412-1422, 2000
13. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
14. Gelman RS, Taylor SG 4th: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984
15. Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group. Cancer 52: 1986-1992, 1983
16. Ibrahim N, Frye D, Buzdar A, et al: Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: Tolerance and outcome. Arch Intern Med 156:882-888, 1996
17. Adami H-O, Malker B, Meirik O, et al: Age as a prognostic factor in breast cancer. Cancer 56:898-902, 1985
18. Eppenberger-Castori S, Moore DH Jr, Thor AD, et al: Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34:1318-1330, 2002
19. Lippman ME, Allegra JC, Thompson EB, et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
20. Albain KS, Green S, Ravdin P, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100. Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
21. Colleoni M, Litman HJ, Castiglione-Gertsch M, et al: Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86:1705-1714, 2002
22. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
23. Gelber R, Goldhirsch A: A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772-1779, 1986
24. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991
25. ATAC Trialists' Group T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
26. Goss PE, Ingle JN, Martino S. et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
27. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
28. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 21:2597-2599, 2003
29. Ravdin P, Green S, Aibain K, et al: Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 324)
30. Paik S, Shak S, Tang G, et al: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP B-20 and B-14. Breast Cancer Research and Treatment 82:S11, 2003 (abstr 16)
31. Stearns V, Davidson NE, Flockhart DA: Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4:143-153, 2004